CeMM Seminar Rooms, Level 8
The "1st Vienna Symposium on Machine Learning in Biology & Medicine" is designed as a community gathering and a networking opportunity for machine learning researchers from all of Austria - following the success of similar meetings in the areas of next generation sequencing ("Vienna NGS Symposium") and chemical biology ("Austrodrugs") organized at CeMM. The scientific focus will be on new machine learning methods and relevant applications of machine learning and artificial intelligence in biology and medicine.
Short invited talks by leading researchers from Austria
Keynote lecture, followed by networking reception
Machine learning methods and applications • Biomedical data science • Image analysis •Genomics • Computational neuroscience • Chemoinformatics• Cancer Immunology • Bioinformatics • Digital medicine • Drug discovery • Explainable AI • Ethics & Society
Registration for the symposium is now closed, since we are fully booked.
If you would like to submit your name for the waiting list, please send an email to eschweng(at)cemm(dot)at.
CeMM Level 8, Seminar Room
Professor of Genome Biology, ETH Zurich, Switzerland
"Watching CRISPR genome editing at work in human cells"
Host: Joanna Loizou
Jacob Corn is the Professor of Genome Biology at the ETH Zurich. His research aims to better understand and treat disease through next-generation genome editing technologies. Jacob’s career has bridged academia and industry, working in therapeutic areas that include infectious disease, neurobiology, and oncology. His research takes a multidisciplinary approach, combining cellular biochemistry, functional genomics, computational biology, bioengineering, and biophysics. Jacob’s graduate studies at the University of California, Berkeley with James Berger redefined our understanding of the geometry of DNA replication and was recognized with several honors, including the Nicholas Cozzarelli and Harold Weintraub awards. Jacob’s work as a Jane Coffin Childs postdoctoral fellow at the University of Washington culminated in the world’s first computationally designed de novo protein interaction and a protein-based inhibitor to treat flu. Jacob began his independent research career as a group leader at Genentech, where his lab discovered biological mechanisms for challenging therapeutic targets. Jacob then moved back to academia as the founding Scientific Director of the Innovative Genomics Institute and faculty at UC Berkeley. His lab’s current focus is the development of genome editing, the mechanisms by which cells repair their DNA, and the maintenance of healthy organelles. In his spare time, Jacob enjoys long backpacking trips and rock climbing.